GINKGO BIOWORKS HOLDINGS INC (DNA) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:DNA - US37611X2099 - Common Stock
9.24 USD
+0.18 (+1.99%)
9.3143 USD
+0.07 (+0.8%)
DNA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. DNA has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, DNA is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year DNA has reported negative net income.
DNA had a negative operating cash flow in the past year.
DNA had negative earnings in each of the past 5 years.
DNA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -28.55%, DNA is not doing good in the industry: 73.68% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -60.66%, DNA is doing worse than 75.44% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.55% | ||
| ROE | -60.66% | ||
| ROIC | N/A |
ROA(3y)-58.74%
ROA(5y)-56.67%
ROE(3y)-93%
ROE(5y)-85.6%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
DNA's Gross Margin of 72.71% is amongst the best of the industry. DNA outperforms 96.49% of its industry peers.
In the last couple of years the Gross Margin of DNA has declined.
The Profit Margin and Operating Margin are not available for DNA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 72.71% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y11.07%
GM growth 5Y-4.27%
2. Health
2.1 Basic Checks
DNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, DNA has more shares outstanding
The number of shares outstanding for DNA has been reduced compared to 5 years ago.
Compared to 1 year ago, DNA has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -7.04, we must say that DNA is in the distress zone and has some risk of bankruptcy.
DNA has a Altman-Z score of -7.04. This is amonst the worse of the industry: DNA underperforms 89.47% of its industry peers.
There is no outstanding debt for DNA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -7.04 |
ROIC/WACCN/A
WACC10.93%
2.3 Liquidity
DNA has a Current Ratio of 4.39. This indicates that DNA is financially healthy and has no problem in meeting its short term obligations.
DNA's Current ratio of 4.39 is fine compared to the rest of the industry. DNA outperforms 71.93% of its industry peers.
A Quick Ratio of 4.39 indicates that DNA has no problem at all paying its short term obligations.
DNA has a better Quick ratio (4.39) than 78.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.39 | ||
| Quick Ratio | 4.39 |
3. Growth
3.1 Past
DNA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 45.06%, which is quite impressive.
DNA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -17.13%.
Measured over the past years, DNA shows a very strong growth in Revenue. The Revenue has been growing by 33.17% on average per year.
EPS 1Y (TTM)45.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-54.26%
Revenue 1Y (TTM)-17.13%
Revenue growth 3Y-10.23%
Revenue growth 5Y33.17%
Sales Q2Q%-56.39%
3.2 Future
DNA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.86% yearly.
The Revenue is expected to grow by 10.14% on average over the next years. This is quite good.
EPS Next Y36.23%
EPS Next 2Y22.25%
EPS Next 3Y15.82%
EPS Next 5Y14.86%
Revenue Next Year-23.62%
Revenue Next 2Y-9.48%
Revenue Next 3Y2%
Revenue Next 5Y10.14%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
DNA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year DNA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
DNA's earnings are expected to grow with 15.82% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.25%
EPS Next 3Y15.82%
5. Dividend
5.1 Amount
No dividends for DNA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
9.24
+0.18 (+1.99%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners63.41%
Inst Owner Change0%
Ins Owners3.44%
Ins Owner Change-0.01%
Market Cap532.13M
Revenue(TTM)180.61M
Net Income(TTM)-339.55M
Analysts41.82
Price Target10.88 (17.75%)
Short Float %14.05%
Short Ratio5.72
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)7.35%
Min EPS beat(2)-15.78%
Max EPS beat(2)30.48%
EPS beat(4)2
Avg EPS beat(4)2.21%
Min EPS beat(4)-15.78%
Max EPS beat(4)30.48%
EPS beat(8)5
Avg EPS beat(8)9.77%
EPS beat(12)6
Avg EPS beat(12)1.99%
EPS beat(16)6
Avg EPS beat(16)-240.57%
Revenue beat(2)1
Avg Revenue beat(2)8.5%
Min Revenue beat(2)-1.02%
Max Revenue beat(2)18.03%
Revenue beat(4)2
Avg Revenue beat(4)9.57%
Min Revenue beat(4)-2.36%
Max Revenue beat(4)23.63%
Revenue beat(8)4
Avg Revenue beat(8)15.72%
Revenue beat(12)8
Avg Revenue beat(12)14.38%
Revenue beat(16)12
Avg Revenue beat(16)23.68%
PT rev (1m)0%
PT rev (3m)-5.88%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-14.96%
EPS NY rev (1m)0%
EPS NY rev (3m)-7.46%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-7.65%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.76%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 2.95 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.95 | ||
| P/tB | 1.07 | ||
| EV/EBITDA | N/A |
EPS(TTM)-6.23
EYN/A
EPS(NY)-4.52
Fwd EYN/A
FCF(TTM)-3.25
FCFYN/A
OCF(TTM)-2.88
OCFYN/A
SpS3.14
BVpS9.72
TBVpS8.65
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.55% | ||
| ROE | -60.66% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 72.71% | ||
| FCFM | N/A |
ROA(3y)-58.74%
ROA(5y)-56.67%
ROE(3y)-93%
ROE(5y)-85.6%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y11.07%
GM growth 5Y-4.27%
F-Score4
Asset Turnover0.15
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 35.04% | ||
| Cap/Sales | 11.83% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.39 | ||
| Quick Ratio | 4.39 | ||
| Altman-Z | -7.04 |
F-Score4
WACC10.93%
ROIC/WACCN/A
Cap/Depr(3y)93.32%
Cap/Depr(5y)178.3%
Cap/Sales(3y)18.24%
Cap/Sales(5y)29.62%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)45.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-54.26%
EPS Next Y36.23%
EPS Next 2Y22.25%
EPS Next 3Y15.82%
EPS Next 5Y14.86%
Revenue 1Y (TTM)-17.13%
Revenue growth 3Y-10.23%
Revenue growth 5Y33.17%
Sales Q2Q%-56.39%
Revenue Next Year-23.62%
Revenue Next 2Y-9.48%
Revenue Next 3Y2%
Revenue Next 5Y10.14%
EBIT growth 1Y19.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year70.58%
EBIT Next 3Y26.55%
EBIT Next 5Y15.81%
FCF growth 1Y53.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y51.54%
OCF growth 3YN/A
OCF growth 5YN/A
GINKGO BIOWORKS HOLDINGS INC / DNA FAQ
What is the ChartMill fundamental rating of GINKGO BIOWORKS HOLDINGS INC (DNA) stock?
ChartMill assigns a fundamental rating of 3 / 10 to DNA.
What is the valuation status for DNA stock?
ChartMill assigns a valuation rating of 0 / 10 to GINKGO BIOWORKS HOLDINGS INC (DNA). This can be considered as Overvalued.
How profitable is GINKGO BIOWORKS HOLDINGS INC (DNA) stock?
GINKGO BIOWORKS HOLDINGS INC (DNA) has a profitability rating of 1 / 10.
What is the earnings growth outlook for GINKGO BIOWORKS HOLDINGS INC?
The Earnings per Share (EPS) of GINKGO BIOWORKS HOLDINGS INC (DNA) is expected to grow by 36.23% in the next year.